Symptoms: increased manifestations of side effects.
Treatment: symptomatic therapy.
hypersensitivity to the components of the drug,
tachyarrhythmia, myocarditis,
heart defects,
decompensated diabetes mellitus,
thyrotoxicosis,
glaucoma,
liver or kidney failure,
peptic ulcer of the stomach and duodenum in the acute stage,
gastric bleeding,
arterial hypertension,
pregnancy,
lactation period,
children under 6 years of age.
With caution it is prescribed to patients with diabetes mellitus, gastric ulcer and duodenal ulcer in remission.
Other betas2- adrenomimetic agents and theophylline enhance the effect of salbutamol and increase the likelihood of side effects.
Ascoril is not prescribed simultaneously with drugs containing codeine and other antitussive agents, because this makes it difficult to discharge liquefied sputum.
Ascoril bromhexine, which is part of the drug, promotes the penetration of antibiotics (erythromycin, cephalexin, oxytetracycline) into the lung tissue.
It is not recommended to use the drug Ascoril simultaneously with non-selective beta-blockers, such as propranolol.
Ascoril salbutamol, which is part of the drug, is not recommended for patients who receive MAO inhibitors.
Diuretics and corticosteroids increase the hypokalemic effect of salbutamol.
It is not recommended to take at the same time with the drug Ascoril alkaline drink.
White, round, flat tablets with a chamfer and a one-sided risk.
According to WHO, adverse effects are classified according to their frequency of development as follows: very common (≥1/10), common (≥1/100 to <1/10), infrequent (≥1/1000 to <1/100), rare (≥1/10000 to <1/1000), very rare (<1/10000), frequency unknown — according to available data, it was not possible to determine the frequency of occurrence.
On the part of the immune system: rarely-hypersensitivity reactions, frequency unknown-anaphylactic reactions, including anaphylactic shock, angioedema, and pruritus.
From the central nervous system: rarely-headache, dizziness, increased nervous excitability, sleep disturbance, drowsiness, tremor, convulsions.
From the CCC side: rarely-rapid heartbeat, collapse.
From the respiratory system, chest and mediastinal organs: rarely-bronchospasm.
From the gastrointestinal tract: rarely — nausea, vomiting, diarrhea, exacerbation of gastric ulcer and duodenal ulcer.
From the kidneys and urinary system: rarely-it is possible to stain the urine in pink.
From the skin and subcutaneous tissues: rarely-rash, urticaria, frequency unknown-severe skin adverse reactions (including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis and acute generalized exanthematous pustulosis associated with the use of ambroxol (ambroxol is a metabolite of bromhexine).
According to the recipe.
There are reports of severe skin reactions, such as erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis, associated with the use of ambroxol. Since ambroxol is a metabolite of bromhexine, the risk of anaphylactic and severe skin reactions can also be considered for bromhexine.
If symptoms of a progressive skin reaction occur (sometimes associated with damage to the mucous membranes of the mouth, throat, nose, eyes, and genitals), you should immediately stop using Ascoril and consult a doctor.
Guaifenesin turns the urine pink.
It is not recommended to take an alkaline drink at the same time with the drug.
As part of combination therapy for acute and chronic bronchopulmonary diseases, accompanied by the formation of a viscous secretion that is difficult to separate:
bronchial asthma,
tracheobronchitis,
obstructive bronchitis,
pneumonia,
emphysema of the lungs,
whooping cough,
pneumoconiosis,
tuberculosis of the lungs.
The combined drug has a bronchodilator, expectorant and mucolytic effect.
Bromhexine - mucolytic agent, has an expectorant effect. Increases the serous component of bronchial secretions, activates the cilia of the ciliated epithelium, reduces the viscosity of sputum, increases its volume and improves discharge.
Guaifenesin - mucolytic agent, reduces the surface tension of the structures of the bronchopulmonary apparatus, stimulates the secretory cells of the bronchial mucosa that produce neutral polysaccharides, depolymerizes acidic mucopolysaccharides, reduces the viscosity of sputum, activates the ciliary apparatus of the bronchi, facilitates the removal of sputum and promotes the transition of unproductive cough to productive.
Salbutamol — bronchodilator remedy stimulates the beta2- adrenoreceptors of the bronchi, blood vessels and myometrium. Prevents or eliminates bronchial spasm, reduces resistance in the respiratory tract, increases the vital capacity of the lungs. Causes dilation of the coronary arteries, does not reduce blood pressure.
Bromhexine. When taken orally, it is almost completely (99%) absorbed into the gastrointestinal tract within 30 minutes. Bioavailability is low (the effect of primary passage through the liver). Penetrates through the placental barrier and BBB. In the liver, it undergoes demethylation and oxidation, and is metabolized to pharmacologically active ambroxol. T1/2 - 15 h (due to slow reverse diffusion from the tissues). It is excreted by the kidneys. With CRF, the excretion of metabolites is disrupted. With repeated use, it can accumulate.
Guaifenesin. Absorption from the gastrointestinal tract is rapid (25-30 minutes after ingestion). T1/2 - 1 h. Penetrates into tissues containing acidic mucopolysaccharides. Approximately 60% of the administered guaifenesin is metabolized in the liver. It is excreted by the lungs (with sputum) and kidneys both in unchanged form and in the form of inactive metabolites.
Salbutamol. When ingested, the absorption is high. Food intake reduces the rate of absorption, but does not affect bioavailability. The binding to plasma proteins is 10%. Penetrates through the placenta. It undergoes presystemic metabolism in the liver and intestinal wall, and is inactivated to 4-o-sulfate ether by phenolsulfotransferase. T1/2 - 3.8-6 hours. It is excreted by the kidneys (69-90%), mainly in the form of an inactive phenol sulfate metabolite (60%) for 72 hours and with bile (4%). The bioavailability of orally administered salbutamol is about 50%.
In a dry place, protected from light, at a temperature not exceeding 25 °C.
Keep out of reach of children.
The shelf life of the drug is accelerated2 года.Do not use after the expiration date indicated on the package.
| Pills | 1 table. |
| active ingredients: | |
| bromhexine hydrochloride | 8 mg |
| guaifenesin | 100 mg |
| salbutamol sulfate (equivalent to salbutamol) | 2 mg |
| excipients: calcium hydrophosphate, corn starch, methylparahydroxybenzoate( methylparaben), propylparahydroxybenzoate (propylparaben), purified talc, colloidal silicon dioxide, magnesium stearate |
Pills. According to 10 tables. in a contour cell packaging made of light-proof PVC film/aluminum foil. 1, 2 or 5 packages are placed in a cardboard pack.
During pregnancy, it is not recommended to use the drug.
If necessary, treatment with the drug during lactation, breastfeeding should be discontinued.
Inside, 3 times a day. Adults and children over 12 years — 1 table., children from 6 to 12 years-1/2 or 1 table.
Children under the age of 6 years are recommended to use Ascoril expectorant syrup.
R05C Expectorants, other than combinations with antitussives
